Does vitamin B12 deficiency exacerbate psoriatic arthritis?

Does Vitamin B12 Deficiency Worsen Psoriatic Arthritis?

There is no evidence that vitamin B12 deficiency directly worsens psoriatic arthritis disease activity, though B12 deficiency is common in PsA patients and can cause overlapping neuropsychiatric symptoms that complicate clinical assessment.

Current Evidence on B12 and Psoriatic Arthritis

Prevalence Without Disease Impact

• Low serum B12 levels occur frequently in psoriatic arthritis patients (approximately 24% prevalence), similar to rates seen in rheumatoid arthritis and systemic lupus erythematosus 1
• Critically, no correlation exists between serum B12 levels and disease severity in psoriatic arthritis—neither PASI scores nor psoriasis type correlate with B12 status 2
• Among patients with low serum B12, true tissue deficiency (confirmed by elevated methylmalonic acid or homocysteine) occurs in only 26% of cases, suggesting most low values represent laboratory findings without clinical significance 1

The Symptom Overlap Problem

• B12 deficiency causes neuropathic pain, fatigue, muscle weakness, and depression—symptoms that mimic and overlap with psoriatic arthritis manifestations 3
• These overlapping symptoms are frequently misattributed to the rheumatic disease itself without proper evaluation for B12 deficiency 3
• In rheumatic patients with these symptoms, B12 supplementation can provide substantial symptomatic relief even when laboratory deficiency is not clearly documented 3

Clinical Management Algorithm

When to Test B12 in PsA Patients

Test vitamin B12 levels when patients present with:

• Neuropathic pain or peripheral neuropathy 3
• Unexplained fatigue beyond what is expected from disease activity 3
• Depression or cognitive difficulties 3
• Muscle weakness 3
• Anemia (present in 35% of PsA patients) 1

Interpreting Results

• If serum B12 is low, measure homocysteine and methylmalonic acid to confirm true tissue deficiency 1
• Elevated homocysteine with low B12 occurs more commonly than elevated MMA in rheumatic patients 1
• Consider supplementation even with borderline-low B12 if neuropsychiatric symptoms are prominent, given the nerve-protecting properties of cobalamin 3

Important Caveats

B12 Does Not Treat PsA Itself

• The 2024 EULAR guidelines for psoriatic arthritis management make no mention of vitamin supplementation as disease-modifying therapy 4
• Treatment goals focus on controlling inflammation through DMARDs, biologics, and JAK inhibitors—not nutritional interventions 4
• While vitamin B12 may ameliorate psoriasis through suppression of inflammatory pathways, this applies to skin disease rather than joint manifestations 5

Medication Interactions

• Methotrexate (the preferred csDMARD for PsA with skin involvement) increases B12 deficiency risk 6
• Patients on methotrexate warrant closer B12 monitoring 6

Emerging Contradictory Data

• A 2025 study suggests that higher B12 intake may paradoxically increase osteoarthritis risk, particularly in women over 65 7
• This finding raises caution about indiscriminate B12 supplementation in inflammatory arthritis patients, though the mechanism and applicability to PsA remain unclear 7

Practical Approach

Assess B12 status early in PsA patients with neuropsychiatric symptoms, but recognize that correcting deficiency treats overlapping symptoms rather than the underlying arthritis. Continue evidence-based PsA management with DMARDs and biologics per EULAR guidelines while addressing B12 deficiency as a separate comorbidity 4, 3.